Disclosures for "Recurrent Glioblastoma in the age of Immunovirotherapy: Cross-trial Evidence of Safety, Efficacy, and Immune Activation"
-
Ms. Kehtari has nothing to disclose.
-
Dr. Odia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PharPoint. Dr. Odia has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GammaTile. Dr. Odia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chimeric, part of Jazz Pharmaceuticals.